We use cookies on this site in order to make it works, and for the traffic analysis.
You can refuse or configure cookies by purposes.
Another message from the Google Adsense consent management platform will ask you for your choices relating to the use of your personal data via cookies for advertising.
We thank you to accept cookies which makes this site work.

Dealing with uncertainty in uveal melanoma prognostication

Dear colleague,

I am currently a resident in medical oncology at Institut Curie, Paris, France. Within the time frame of obtaining my Master of Science degree in Medical Ethics, I am working on a project about how prognosis is established and communicated to patients with uveal melanoma.
As you know, practices and guidelines are heterogeneous among countries and ophthalmologists. For example, some physicians perform biopsies and propose prognostic molecular testing, such as gene expression profiles or cytogenetic analysis, whereas others do not.

My main questions are how clinicians establish and communicate prognosis to patients and what are the factors influencing such communication.

In order to answer these questions, I would like to invite you to participate in a short confidential survey that will take about five minutes.

mandatory answer

Question 1

Country of practice?

mandatory answer

Question 2

How long have you worked in the field of uveal melanoma (UM)?

Question 3

How many new patients with UM do you take care of each year?

Question 4

How do you assess UM prognosis in routine practice?

Comments

mandatory answer

Question 5

Do you request patient consent before prognosis testing when an enucleation is recommended?

Comments

mandatory answer

Question 6

When accessible, do you perform a fine-needle aspiration biopsy (FNAB) in these cases? If so, why?

Comments

Question 7

What information do you give to patients before performing FNAB?

Comments

Question 8

Do you ask for signed consent before FNAB?

Comments

mandatory answer

Question 9

In your opinion, how often do patients ask about their prognosis?

Comments

mandatory answer

Question 10

Do you provide the patient with survival statistics?

uncheck

Comments

Question 11

Do you personally explain to patients their level of metastatic risk?

Question 12

Is yes, how do you communicate prognosis to patients at high risk of metastatic recurrence?

Question 13

Is another health care professional in charge of informing patients?

Comments

Question 14

If yes, who?

uncheck

Question 15

If you want to have the results of this survey, please provide us with your email




You too, create your online questionnaire!
It's free and easy.
Let's go!
▲